Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

351
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
351
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

312
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
312
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

636
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
636
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

419
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
419
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

682
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
682
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

639
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
639

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world experience of using vitamin E for symptomatic management of muscle cramps in children living with chronic kidney disease.

Pediatric nephrology (Berlin, Germany)·2026
Same author

Atypical renal phenotype with tubular proteinuria and hypercalciuria in siblings with nail-patella syndrome: evidence for a dual genetic diagnosis.

Pediatric nephrology (Berlin, Germany)·2026
Same author

Cystatin-C outperforms creatinine for estimating renal function in adolescents with anorexia nervosa: cross-sectional method-comparison study.

Journal of eating disorders·2026
Same author

Urinary CXCL9 and CXCL10, Interstitial Inflammation and Disease Activity Over Time in Acute Interstitial Nephritis.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same author

IgA Nephropathy Across the Age Spectrum: Urgent Need to Accelerate Pediatric Access to Therapeutic Innovation.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Outcomes and Validation of Histopathological Scores in Pediatric ANCA-vasculitis.

Kidney international reports·2026

Related Experiment Video

Updated: Mar 16, 2026

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

2.2K

Hydroxychloroquine use in pediatric IgA nephropathy.

Karma Abukasm1,2, Lison Lachize Neanne3,4, Andrea Lafitte3

  • 1CHU Sainte-Justine Research Center, Montreal, QC, Canada. karma.abukasm@umontreal.ca.

Pediatric Nephrology (Berlin, Germany)
|March 15, 2026
PubMed
Summary

Hydroxychloroquine (HCQ) significantly reduced proteinuria in children with difficult-to-control IgA nephropathy (cIgAN). This treatment demonstrated a good safety profile, maintaining stable kidney function in pediatric patients.

Keywords:
GlomerulonephritisHydroxychloroquineIgA nephropathyTreatment options

More Related Videos

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

2.0K
Detecting Abnormalities in Choroidal Vasculature in a Mouse Model of Age-related Macular Degeneration by Time-course Indocyanine Green Angiography
10:24

Detecting Abnormalities in Choroidal Vasculature in a Mouse Model of Age-related Macular Degeneration by Time-course Indocyanine Green Angiography

Published on: February 19, 2014

14.1K

Related Experiment Videos

Last Updated: Mar 16, 2026

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

2.2K
Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

2.0K
Detecting Abnormalities in Choroidal Vasculature in a Mouse Model of Age-related Macular Degeneration by Time-course Indocyanine Green Angiography
10:24

Detecting Abnormalities in Choroidal Vasculature in a Mouse Model of Age-related Macular Degeneration by Time-course Indocyanine Green Angiography

Published on: February 19, 2014

14.1K

Area of Science:

  • Pediatric Nephrology
  • Immunology
  • Pharmacology

Background:

  • Adult IgA nephropathy shows potential benefit from hydroxychloroquine (HCQ).
  • HCQ targets toll-like receptors implicated in IgA nephropathy pathogenesis.
  • Childhood-onset IgA nephropathy (cIgAN) requires effective treatment options.

Purpose of the Study:

  • To investigate the efficacy and safety of HCQ in pediatric patients with cIgAN.
  • To assess the impact of HCQ on proteinuria and kidney function in children.
  • To evaluate HCQ as an adjunctive therapy for steroid-sparing in cIgAN.

Main Methods:

  • Retrospective multicenter cohort study of 16 children with biopsy-proven cIgAN.
  • HCQ administered as adjunctive therapy for persistent proteinuria or steroid-sparing.
  • Collected clinical, histological, urine protein-to-creatinine ratio (UPCR), and estimated glomerular filtration rate (eGFR) data.
  • Compared kidney biopsies before and after HCQ initiation.

Main Results:

  • Significant reduction in UPCR observed at 3, 6, 9, and 12 months post-HCQ initiation (50% decrease at 12 months).
  • Estimated glomerular filtration rate (eGFR) remained stable throughout the follow-up period.
  • Kidney biopsies showed stable or improved Oxford scores post-HCQ treatment.
  • No HCQ-related complications were reported.

Conclusions:

  • HCQ use in children with cIgAN is associated with sustained proteinuria reduction and stable kidney function.
  • This study represents the first pediatric cohort data on real-world HCQ use in cIgAN.
  • Findings support further prospective trials of HCQ as a safe adjunctive treatment for selected cIgAN cases.